ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Kevin R Kelly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.